Video guest: Josephine Mwangi

September 2017
M T W T F S S
28 29 30 31 1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 1



SELECT_TAGS :
















Twitter

Follow the CTA Brussels Daily

 

twitter logo

 

facebook logo cta

EDITO
Monday, 25 September 2017
The Commission has published in July a Communication proposing a “Brussels consensus” on development cooperation as well as guidelines for implementation of development policy by the Community to be discussed and agreed jointly by the three institutions by the end of the year. This will serve as a basis to discuss the challenges ahead for European development Co-operation in the context of the Millenium Development Goals (MDGs) stock-taking event. Coherence and quality of aid in practice are at the top of the agenda for an improved effectiveness. The state of the discussions between the three institutions will also be debated as well as the willingness of Member States to commit into a Declaration on
EU development policy. The European Commissioner for Development, Louis Michel, will be one of the speakers.
The European Association of Development Research and Training Institutes (EADI) is an independent and non-profit making international non-governmental organisation which turns 30 this year.
Monday, 19 September 2005
The Director of CTA, Dr Hansjörg Neun, made a presentation to the ACP Group of COREPER at the EU Council of Ministers in Brussels on 6th September 2005.

Dr Hansjörg Neun talked about the main achievements of CTA and the need, on the basis of the evaluations carried out, to make some strategic choices. He reminded the audience that approximately 8,000 ACP organisations (including farmers’ associations, NGOs, government ministries and other public sector institutions) have benefited directly from CTA’s products and services each year, while about 80 local, national and regional organisations from the 6 ACP regions receive more targeted support.
For the first time in its twenty-year history, CTA will strive to formulate a 5-year plan that seeks to expand the Centre’s impact further building on its strengths that can be summarised as follows: (i)strong networking with a large number of ACP organisations and stakeholders, as well as established relations with several EU and international organisations; (ii)a rich variety of successful products and services iii)a sound knowledge base and over twenty years of expertise in its area of competence.

The COREPER Group congratulated the new Director for his excellent and very informative presentation which enhances the knowledge about CTA,as well as the concrete examples on how CTA operates with actors in the field.
The group encouraged the director on issues such as the comparative advantage of CTA compared with other international organizations, the need to further develop CTA's direct contact with the final users and farmers (services such as the Question and Answer Service) and the need to share information with other organizations.

See attached the presentation.
At the Summit, which ended yesterday, world leaders took up the challenge of making the UN more efficient, effective and relevant. The European Union (EU) believes that the Summit Outcome is a clear milestone along the road of reform. It is a clear mandate for change, addressing challenges that the world has long faced - and others that the world is facing for the first time.

Summit Outcome on Development
The Summit provided the foundation for strengthening the global partnership between developed and developing countries set out at Monterrey. Earlier this year, the EU set a timetable to reach new levels of Official Development Assistance. By 2010, this assistance will account for 0.56 per cent of the EU's collective Gross National Income - resulting in an annual additional 20 billion Euros. By 2015 this proportion will reach 0.7 per cent. And EU member states recently agreed to support the G8 agreement to write off debt. In addition, the Summit recognised the value of developing innovative sources of financing. Sub-Saharan Africa is not on target to reach many of the goals for over 100 years and on some goals - including hunger and sanitation - the situation is actually going backwards. At least 50 per cent of the agreed increase in EU aid resources, therefore, will go to Africa; in plain terms this means a doubling of EU aid to Africa over the next five years. More aid on its own will not be enough. The real engines for making poverty history will be developing countries themselves. The EU believes that, as important as increasing aid, is making sure that it is used better and more effectively, in order to drive up standards of governance and help the poorest people for whom it is intended. This means developing countries adopting ambitious national development strategies, creating and reinforcing good governance structures, fostering a positive environment for economic growth and helping the private sector flourish. The EU welcomes the strong and comprehensive commitments made in this regard by the African countries through the African Union, and its NEPAD initiative, and reflected in the Summit Outcome.

Some would say that not enough progress was made on trade at the Summit. The EU believes that, through the Doha Round, the international community must deliver real gains for poor countries by reducing market barriers, abolishing export subsidies and significantly reducing trade-distorting domestic support, so that these countries can trade their way to higher growth and more jobs.
  • Bookmark and Share
  • Email
  • Print
Sunday, 18 September 2005
A resolution calling on the EU to give neglected diseases in developing countries a higher priority in its research programme was passed last week by the European Parliament. John Bowis MEP, health spokesman for the Group of the European People's Party (EPP), gained solid support for his report, which was written in response to a new Commission programme aimed at tackling HIV/AIDS, malaria and TB. The report, adopted at a plenary session in Strasbourg on 8 September, highlights the lack of research that the EU carries out into lesser-known diseases such as sleeping sickness and dengue fever. So far, the pharmaceutical industry has been unable to meet the needs of people with neglected diseases, as often the potential returns for shareholders are unclear. Even if the industry continues to play a major part in the discovery and development of drugs, a much greater pluralism in both the funding and discovery of novel treatments is needed, according to the resolution.

'The European Union is right to be addressing HIV, TB and malaria in the developing world, but there are many other diseases that also merit attention,' says Mr Bowis. The report calls for urgent action to develop new drugs and to make them available to developing countries at affordable prices. It also draws attention to the rapidly increasing number of cases of mental illness in many developing countries. Cost-effective treatments exist for most of these disorders but appropriate mental health legislation, treatment and community care are not the priorities that they should be. Between 1975 and 1999 less than one per cent of new drugs placed on the market were developed for infectious tropical diseases. Patients suffering from parasitic infections such as trachoma or potentially fatal leishmaniasis are often given archaic drugs which can be highly toxic, ineffective or difficult to administer. The Parliament resolution, tabled by the development committee, calls on the Commission to increase the amount of funding available for biomedical research into poverty-related diseases such as malaria and TB, and for specific reference to be made in the Seventh Framework Programme (FP7) on funding for research into these diseases. The European Parliament, which wants the umbrella term of neglected diseases to be widened beyond HIV/AIDS, malaria and TB, also calls on the Commission to strengthen the capacity of developing countries to conduct both clinical trials and operational and health systems research. The needs of women, children and disabled people must, it argues, be mainstreamed into health policies and related research.

Given the lack of obvious profitability for companies in this field, the report calls for the pharmaceutical industry to be obliged, or offered incentives, to reinvest a percentage of its profits into neglected disease R&D. The resolution recommends establishing a new global medical R&D treaty and incorporating technology transfer into development policies.
The resolution coincided with the publication of a new report by a team from the London School of Economics Health and Social Care research centre, led by Dr Mary Moran. It argues that a profound change in research into ten so-called 'neglected diseases', including malaria, tuberculosis (TB), leprosy and sleeping sickness, could result in at least eight new drugs being developed by 2010. Moreover, the report highlights that around three-quarters of these research projects are being conducted under the umbrella of public-private partnerships, demonstrating that PPPs have been a critical driver of this considerable increase in activity, and recommending that policy makers should support them when it comes to neglected disease research and development.
Saturday, 17 September 2005
public consultation on whether and how to create a European Institute of Technology (EIT) has been opened by the European Commission today. It will gather the views of stakeholders on how an ‘EIT’ could strengthen research, education and market innovation in Europe. The public consultation will run until mid-November, and will feed into a wider analysis by the European Commission services.